COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #219 of 237
12/23 Late treatment study
Taccone et al., The Lancet Regional Health - Europe, doi:10.1016/j.lanepe.2020.100019 (Peer Reviewed)
The role of organizational characteristics on the outcome of COVID-19 patients admitted to the ICU in Belgium
Source   PDF   Share   Tweet
Retrospective 1,747 ICU patients in Belgium showing lower mortality with HCQ, multivariate mixed effects analysis HCQ aOR 0.64 [0.45-0.92].

Taccone et al., 12/23/2020, retrospective, Belgium, Europe, peer-reviewed, 10 authors.
risk of death, 24.7% lower, RR 0.75, p < 0.001, treatment 449 of 1308 (34.3%), control 183 of 439 (41.7%), odds ratio converted to relative risk.
Details of all 237 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit